Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Intralesional triamcinolone acetonide is effective for treating patchy hair loss, and dermoscopy helps detect treatment response and side effects early.

Alopecia Areata is a complex, unpredictable autoimmune hair loss condition with limited treatment options and a significant psychological impact.

Topical minoxidil effectively and safely treats extensive alopecia areata but doesn't change its course.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.

Diagnosing hair loss disorders needs clinical, dermoscopic, and histological differences, and checking menstrual cycle, weight changes, drug therapy, and nail changes.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

JAK inhibitors may soon be a safe and effective treatment for alopecia areata.

Minoxidil helps hair regrowth in alopecia, but more research needed.

Different treatments for alopecia areata have unpredictable results and varying success rates.

Laser and light therapies, especially the 308 nm excimer laser, are effective and safe for treating alopecia areata, but more research is needed.

Latanoprost works better for hair growth, and combining it with betamethasone valerate is most effective.

Patients with severe alopecia areata have higher levels of MIF, which decrease after successful treatment.

Alopecia areata causes varying hair loss patterns, affecting hair, nails, and possibly glands, with treatment outcomes depending on disease duration and extent.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

A 3-year-old boy lost all his hair due to a rare reaction to phenobarbital, but it grew back after steroid treatment.

The study found no significant difference in stress hormone levels between people with alopecia areata and healthy individuals, suggesting that the disease is not caused by an overactive stress response system.

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

A child's hair loss from alopecia areata was fully reversed in five months using diet and supplements.

A patient's hair loss may be linked to their diabetes medication, Sitagliptin.

Higher IL-15 levels are linked to more severe hair loss in alopecia areata.

People with alopecia areata often have lower vitamin D levels than healthy people.

Most patients with alopecia areata in Syria are young adult males, often with patchy scalp hair loss.